As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including LeMaitre (NASDAQ: LMAT) and its peers.

The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly.

The 4 surgical equipment & consumables - specialty stocks we track reported a satisfactory Q4. As a group, revenues missed analysts’ consensus estimates by 8.5% while next quarter’s revenue guidance was in line.

Thankfully, share prices of the companies have been resilient as they are up 6% on average since the latest earnings results.

Best Q4: LeMaitre (NASDAQ: LMAT)

Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions.

LeMaitre reported revenues of $64.45 million, up 15.7% year on year. This print exceeded analysts’ expectations by 2.4%. Overall, it was an exceptional quarter for the company with an impressive beat of analysts’ full-year EPS guidance estimates.

Chairman/CEO George LeMaitre said, “International Artegraft growth, higher ASPs and disciplined spending produced 16% Q4 sales growth and 47% op. income growth. Full year 2025 showed similar op. leverage: 14% sales growth & 30% op. income growth. 2026 guidance of $280mm (+12%) in sales and op. income of $77.8mm (+21% adjusted) suggests another year of healthy sales & profit growth.”

LeMaitre pulled off the biggest analyst estimates beat but had the weakest full-year guidance update of the whole group. Unsurprisingly, the stock is up 25.8% since reporting and currently trades at $114.94.

Is now the time to buy LeMaitre? Access our full analysis of the earnings results here, it’s free.

Intuitive Surgical (NASDAQ: ISRG)

Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ: ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties.

Intuitive Surgical reported revenues of $2.87 billion, up 18.8% year on year, outperforming analysts’ expectations by 1%. The business had an exceptional quarter with an impressive beat of analysts’ revenue and EPS estimates.

Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 10.1% since reporting. It currently trades at $472.67.

Is now the time to buy Intuitive Surgical? Access our full analysis of the earnings results here, it’s free.

Teleflex (NYSE: TFX)

With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE: TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide.

Teleflex reported revenues of $569 million, up 28.7% year on year, falling short of analysts’ expectations by 38.3%. It was a disappointing quarter as it posted a significant miss of analysts’ full-year EPS guidance estimates.

Teleflex delivered the fastest revenue growth but had the weakest performance against analyst estimates in the group. Interestingly, the stock is up 12.8% since the results and currently trades at $126.25.

Read our full analysis of Teleflex’s results here.

Integra LifeSciences (NASDAQ: IART)

Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.

Integra LifeSciences reported revenues of $434.9 million, down 1.7% year on year. This result topped analysts’ expectations by 1%. More broadly, it was a mixed quarter as it also produced a solid beat of analysts’ organic revenue estimates but revenue guidance for next quarter missing analysts’ expectations significantly.

Integra LifeSciences scored the highest full-year guidance raise but had the slowest revenue growth among its peers. The stock is down 4.6% since reporting and currently trades at $11.05.

Read our full, actionable report on Integra LifeSciences here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.